Glaucoma QOL questionnaire ticks the right boxes

Article

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension.

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension (OHT), according to the results of a study published online ahead of print by Acta Ophthalmologica Scandinavica.

Alain Béchetoille from Paris and colleagues from across France enrolled patients with OHT or glaucoma (n=573) to take part in a cross-sectional psychometric validation study and a separate reproducibility study (n=244). Each subject answered the 36-item Glau-Qol questionnaire, which was designed from in-depth patient interviews.

The clinical validity of the questionnaire was found to be excellent. It clearly demonstrated that as disease severity and visual field impairment increased, health-related quality of life (HRQoL) scores from psychological wellbeing, self-image, daily life, driving, anxiety and burden of treatment domains were negatively affected. Increased age and lower visual acuity were also associated with lower HRQoL scores but to a lesser extent.

Psychometric validation demonstrated acceptable convergent and discriminant validity of the Glau-QoL and good reproducibility, with intra-class correlation coefficients and concordance correlation coefficients ≥0.69.

It was the conclusion of the researchers that the Glau-QoL questionnaire is a valid instrument that demonstrates excellent correlations with disease progression in patients with glaucoma and OHT.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.